Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
11.45
+0.60 (5.53%)
At close: Sep 2, 2026, 4:00 PM EDT
11.70
+0.25 (2.18%)
Pre-market: Sep 3, 2026, 4:18 AM EDT
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $477.35M in the half year ending June 30, 2026, with 99.22% growth. This brings the company's revenue in the last twelve months to $890.79M, up 167.52% year-over-year. In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth.
Revenue (ttm)
$890.79M
Revenue Growth
+167.52%
P/S Ratio
4.29
Revenue / Employee
$752,352
Employees
1,184
Market Cap
3.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Denali Therapeutics | 3.60M |
TLX News
- 1 day ago - Telix Completes Patient Enrollment In BiPASS Trial, Aligns With FDA On NDA Filing; Stock Up - Nasdaq
- 1 day ago - 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More - Nasdaq
- 1 day ago - Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway - GlobeNewsWire
- 2 days ago - Telix Appoints Gill As Board Chairman - Nasdaq
- 2 days ago - Telix Appoints David Gill as Chair - GlobeNewsWire
- 8 days ago - Telix Pharmaceuticals (ASX:TLX) -- Navigating Regulatory Challenges | WS Amati Global ... - GuruFocus
- 14 days ago - Telix Pharma H1 Revenue Jumps 22%; Reaffirms FY2026 Revenue Guidance; Stock Up - Nasdaq
- 14 days ago - Telix Pharmaceuticals H1 Earnings Call Highlights - MarketBeat